The rise of a grey market in India, where unsupervised doses are sold at exorbitant rates, demonstrates that excessive ...

The latest of those is a bid valued at up to $10 billion for U.S. obesity-drug developer Metsera, up from a previous $9 billion offer it originally made, as it tries to usurp an already agree-on deal ...

Novo launched a rival bid to acquire American obesity biotech firm Metsera last week, superseding an offer for the firm from ...

Intensifying competition, pricing pressure and copycat versions of Ozempic and Wegovy hold back sales at the pharma giant.

Novo Nordisk A/S ( NVO) trimmed its forecast for a fourth time this year on Wednesday, citing lower-than-expected sales of ...

Tallia Oyando and Grace Msalame openly discussed their decision to try Ozempic for weight loss, sharing their health journeys ...

Novo Nordisk, as well as Eli Lilly, would gain Medicare and Medicaid coverage for their blockbuster weight-loss drugs.

The lowest doses of Eli Lilly’s Zepbound and Novo Nordisk's Wegovy could be available for as little as $149 a month.

The Trump administration is nearing deals with drugmakers Eli Lilly and Novo Nordisk to offer some of their obesity drugs to consumers for as low as $149 per month, according to two people familiar ...

Walmart is joining Costco, Sam’s Club, and CVS in offering cheaper prices for customers paying out of pocket for Zepbound, Ozempic, or Wegovy.

The Trump administration plans to announce a deal with pharmaceutical companies to sell discounted weight-loss drugs through ...